Inloggen
E-mail
Wachtwoord
Paswoord weergeven
Bewaren
Bent u uw wachtwoord vergeten?
Gratis lid worden
Registreer
Registreer
Instellingen
Instellingen
Dynamische koersen 
OFFON

Toonaangevende leiders

Alle informatieOndernemingenMarktenEconomie & ForexgrondstoffenRenteToonaangevende leidersFinanciŽle professionalAgendaSectoren 
HomepaginaAl het nieuwsHet meest gelezen nieuwsBiografieŽn van de Leiders
Portrait de David M. Mott
Leeftijd : 54
Vermogen : 25 121 470 USD
Belangrijkste bedrijven : Novavax, Inc. - Mersana Therapeutics, Inc. - Adaptimmune Therapeutics plc - Epizyme, Inc. - Ardelyx, Inc. - IMARA Inc.
Overzicht 
David M. Mott is an American businessperson who founded MedImmune Ventures, Inc. and who has been the head of 18 different companies. Currently, he holds the position of Chairman of Mersana Therapeutics, Inc., Chairman of Epizyme, Inc., Chairman for Ardelyx, Inc., Chairman at Complexa, Inc., Chairman of Cydan II, Inc., Chairman for Cydan LLC (a subsidiary of Cydan II, Inc.), Chairman of Adaptimmune Therapeutics Plc, Chairman of Imara, Inc. and Chairman at Vtesse, Inc. Mr. Mott is also on the board of 5 other companies.

In the past Mr. Mott held the position of Chairman at Zyngenia, Inc., Chairman of Sagimet Biosciences, Inc., Executive Vice President for AstraZeneca Plc Vice Chairman, President & Chief Executive Officer at MedImmune LLC, President & Chief Executive Officer at MedImmune Ltd. and President for MedImmune Ventures, Inc. (which are all subsidiaries of AstraZeneca Plc), General Partner at New Enterprise Associates LLC, General Partner for NEA Management Co. LLC, Chairman of Conceptis Technologies, Inc., Chairman of Tesaro, Inc., Chairman-Supervisory Board for Prosensa Holding NV, Chairman at Adaptimmune Ltd., Vice President-Health Care Investment Banking at Smith Barney Harris Upham & Co., Inc. and VP-Health Care Investment Banking Group at Harris Upham & Co, Inc.

He received an undergraduate degree from Dartmouth College.


Posities en verantwoordelijkheden van David M. Mott 
NaamTitel Van
Novavax, Inc.
(Biotechnologie & Medisch Onderzoek)
Independent Director 2020
Mersana Therapeutics, Inc.
(Biotechnologie & Medisch Onderzoek)
Chairman 2015
Adaptimmune Therapeutics plc
(Biotechnologie & Medisch Onderzoek)
Chairman 2017
Epizyme, Inc.
(Biotechnologie & Medisch Onderzoek)
Chairman 2016
Ardelyx, Inc.
(Biotechnologie & Medisch Onderzoek)
Chairman 2014
IMARA Inc.
(Biotechnologie & Medisch Onderzoek)
Chairman 2016
Cydan II, Inc. Chairman -
Cydan LLC Chairman -
Vtesse, Inc. Chairman -
Biotechnology Innovation Organization Director -
Complexa, Inc. Chairman -
NEA 14 GP Ltd. Director -
XTuit Pharmaceuticals, Inc. Director -
Biohealth Innovation, Inc. Director -


Belangnemingen van David M. Mott 
NaamAandelen%Totale waarde
Novavax, Inc. (NVAX)
(Biotechnologie & Medisch Onderzoek)
64 9610,087%15 495 797 USD
Mersana Therapeutics, Inc. (MRSN)
(Biotechnologie & Medisch Onderzoek)
548 1940,76%7 636 342 USD
Epizyme, Inc. (EPZM)
(Biotechnologie & Medisch Onderzoek)
271 5040,27%1 400 961 USD
Ardelyx, Inc. (ARDX)
(Biotechnologie & Medisch Onderzoek)
417 2840,40%588 370 USD
Adaptimmune Therapeutics Plc00,0000%0 USD
IMARA Inc. (IMRA)
(Biotechnologie & Medisch Onderzoek)
00,0000%0 USD


David M. MottPersoonlijk netwerk 
Meest gelezen nieuws 
15/09BRAD SMITH : Microsoft kondigt inkoop van eigen aandelen aan tot $60 mrd, verhoogt dividend
MR
13/09MARTIN SORRELL : Sorrell's S4 Capital verhoogt winstverwachting tot 40%
MR
14/09STEPHEN SCHERR : Goldman Sachs benoemt Coleman als nieuwe CFO, ter vervanging van Scherr
MR
15/09ILHAM KADRI : Activist Bluebell Capital wil ontslag CEO Solvay
AM
Meer nieuws


© 2021 People and Ownership :   
David M. Mott Verbindingen